Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. How we work/
      3. Collaborations /
      4. Industry & commercial collaborations

      Industry & commercial collaborations

      Collaborations have formed an essential part of our heritage and we are committed to working with our partners to achieve our goal of making disease a thing of the past.

      We build strong, long-term collaborations that help us to learn and to develop better medicines.

      We have more than 150 partnerships, across all aspects of the healthcare spectrum, including projects with large pharmaceutical companies, biotech companies, academic institutions, public-private partnerships and open-campus initiatives.
      JJ_Photo_Colleagues in discussion at the office_IM_1Star.jpg
      Partnering externally through Johnson & Johnson Innovation
      Johnson & Johnson Innovation Ltd seeks to positively impact human health through innovation. We do this by helping external entrepreneurs create healthcare solutions that improve peoples’ lives around the world. We work side by side with innovators throughout their journey, providing a robust exchange of ideas and resources to support them. We are a global network who collaborate across all three sectors: pharmaceuticals, consumer health and medical devices.
      In EMEA, we have created a unique infrastructure that encompasses the whole region. The Innovation Centre, based in London, UK, acts as a gateway into Europe and the wider region, enabling innovators to access a diverse range of experts and ideas to accelerate their innovations. For us, there is no one-size-fits-all model for our collaborations.


      Instead, we tailor our offering according to the individual partner's needs, whether that be providing scientific mentoring and commercialisation expertise, access to laboratory space, seed investment or early-stage funding of R&D collaborations. We also help incubate companies through our JLABS @ BE in Belgium, offering them mentorship and infrastructure. Companies seeking funding can also receive investment through JJDC, which is our strategic venture capital arm.



      Learn more here or follow us on X. You can sign up to our newsletter or email us on [email protected].
      Our support for EFPIA
      We work with the European Federation of Pharmaceutical Industries and Associations (EFPIA) to support a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
      Learn more
      Mother and daughter eating fruit at summer neighborhood block party in park
      Evolution of Healthcare
      It has long been our vision to make disease a thing of the past, but in order to get there, we know healthcare across our region needs to adapt and evolve into a sustainable and resilient ecosystem, prepared for the next generation of therapies. We are partnering to make a meaningful difference for tomorrow.
      August 20, 2024
      Learn more
      Cross-industry collaborations
      • EHDEN
        EHDEN is the European Health Data and Evidence Network. It is a data-sharing system that aims to speed up the health research process. The idea is to enable better health decisions, outcomes and care through a research ecosystem powered by data from more than 100 million sources.
      • MELLODDY
        MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) aims to leverage the world’s largest collection of small molecules with known biochemical or cellular activity to enable more accurate predictive models and increase efficiencies in drug discovery.
      • HONEUR
        HONEUR (Haematology Outcomes Network in Europe) is a federated network of data partners, set up by Janssen. Its collaborative goal is to unlock the transformational potential of real-world data and improve outcomes for people with blood cancers across Europe.
      EUPATI
      We work with the European Patients’ Academy on Therapeutic Innovation (EUPATI) to educate patients about laboratory and pre-clinical research, clinical trials and regulatory approvals. We believe that well-informed patients are an asset to research & development.
      Learn more
      Advocacy collaborations and campaigns
      Johnson & Johsnon cooperates with trade associations, patient groups and other stakeholders to support a favourable external environment for patients and innovation.
      • We Won’t Rest
        We are supporting European Federation of Pharmaceutical Industries and Association’s (EFPIA) We Won’t Rest campaign – a cross-industry collaboration that highlights the importance of innovation to transform the lives of patients.
      • All.Can
        All.Can is a project co-sponsored by J&J Innovative Medicine that aims to improve cancer care and to create sustainable and equal conditions for the care of cancer patients.
      • Breaking Depression
        Breaking Depression aims to raise awareness of the challenges of living with different types of depression, including major depressive disorder (MDD). The campaign has been started by J&J Innovative Medicine, with support from the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Federation of Associations of Families of People with Mental Illness (EUFAMI).
      • My IBD Journey
        My IBD Journey is a campaign that aims to provide support and advice for people who have recently been diagnosed with inflammatory bowel disease (IBD). The animations have been developed in association with the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).

      CP-459038
      September 2024